Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass

Vipula Kolli; Lance A. Stechschulte; Abigail R. Dowling; Sima Rahman; Piotr J. Czernik; Beata Lecka-Czernik

doi:10.1371/journal.pone.0096323

Loading metrics

Open Access

Peer-reviewed

Research Article

Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass

Vipula Kolli,

Current address: Department of Biochemistry, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America

Affiliations Department of Orthopaedic Surgery, University of Toledo College of Medicine, Toledo, Ohio, United States of America, Center for Diabetes and Endocrine Research, University of Toledo College of Medicine, Toledo, Ohio, United States of America
⨯
Lance A. Stechschulte,

Affiliations Department of Orthopaedic Surgery, University of Toledo College of Medicine, Toledo, Ohio, United States of America, Center for Diabetes and Endocrine Research, University of Toledo College of Medicine, Toledo, Ohio, United States of America
⨯
Abigail R. Dowling,

Affiliations Department of Physiology and Pharmacology, University of Toledo College of Medicine, Toledo, Ohio, United States of America, Center for Diabetes and Endocrine Research, University of Toledo College of Medicine, Toledo, Ohio, United States of America
⨯
Sima Rahman,

Affiliations Department of Orthopaedic Surgery, University of Toledo College of Medicine, Toledo, Ohio, United States of America, Center for Diabetes and Endocrine Research, University of Toledo College of Medicine, Toledo, Ohio, United States of America
⨯
Piotr J. Czernik,

Affiliation Department of Orthopaedic Surgery, University of Toledo College of Medicine, Toledo, Ohio, United States of America
⨯
Beata Lecka-Czernik

* E-mail: beata.leckaczernik@utoledo.edu

Affiliations Department of Orthopaedic Surgery, University of Toledo College of Medicine, Toledo, Ohio, United States of America, Department of Physiology and Pharmacology, University of Toledo College of Medicine, Toledo, Ohio, United States of America, Center for Diabetes and Endocrine Research, University of Toledo College of Medicine, Toledo, Ohio, United States of America
⨯

Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass

Vipula Kolli,
Lance A. Stechschulte,
Abigail R. Dowling,
Sima Rahman,
Piotr J. Czernik,
Beata Lecka-Czernik

Published: May 8, 2014
https://doi.org/10.1371/journal.pone.0096323

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.
Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.
Adipocytes
Is the Subject Area "Adipocytes" applicable to this article?

Thanks for your feedback.
Adipose tissue
Is the Subject Area "Adipose tissue" applicable to this article?

Thanks for your feedback.
Glucose metabolism
Is the Subject Area "Glucose metabolism" applicable to this article?

Thanks for your feedback.
Phosphorylation
Is the Subject Area "Phosphorylation" applicable to this article?

Thanks for your feedback.
Osteoblasts
Is the Subject Area "Osteoblasts" applicable to this article?

Thanks for your feedback.
Bone and mineral metabolism
Is the Subject Area "Bone and mineral metabolism" applicable to this article?

Thanks for your feedback.